CN111110913A - Porous Mxene membrane for drug loading and application thereof - Google Patents

Porous Mxene membrane for drug loading and application thereof Download PDF

Info

Publication number
CN111110913A
CN111110913A CN202010064927.7A CN202010064927A CN111110913A CN 111110913 A CN111110913 A CN 111110913A CN 202010064927 A CN202010064927 A CN 202010064927A CN 111110913 A CN111110913 A CN 111110913A
Authority
CN
China
Prior art keywords
drug
mxene
membrane
porous
loaded
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202010064927.7A
Other languages
Chinese (zh)
Other versions
CN111110913B (en
Inventor
闵永刚
刘荣涛
张诗洋
黄兴文
朋小康
王勇
刘屹东
廖松义
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong University of Technology
Dongguan South China Design and Innovation Institute
Original Assignee
Guangdong University of Technology
Dongguan South China Design and Innovation Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangdong University of Technology, Dongguan South China Design and Innovation Institute filed Critical Guangdong University of Technology
Priority to CN202010064927.7A priority Critical patent/CN111110913B/en
Publication of CN111110913A publication Critical patent/CN111110913A/en
Application granted granted Critical
Publication of CN111110913B publication Critical patent/CN111110913B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02—Inorganic materials
    • A61L27/08—Carbon ; Graphite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/56—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus

Abstract

The invention belongs to the technical field of drug loading and tissue engineering biomedical, and discloses a porous Mxene membrane for drug loading and application thereof. The porous Mxene film is prepared by blending and stirring Mxene dispersion liquid, a carbon-based material and polycaprolactone nanoparticles in an inert atmosphere, performing vacuum filtration to form a film, and annealing at 150-500 ℃; wherein, the Mxene is Mn+1XnTxN is 1 to 3, X is C or N, M is a transition metal element of Sc, Ti, Zr, Hf, V, Nb, Ta, Cr, Mo or Mn, TxRepresents a surface functional group, the surface functional group being-O, -OH or-F. The inventionThe medium Mxene material has the characteristics of large porosity, good hydrophilicity, capability of continuously and stably controlling the release of the medicine, good biodegradability and biocompatibility, simple preparation method, simple synthesis and the like.

Description

Porous Mxene membrane for drug loading and application thereof
Technical Field
The invention belongs to the field of drug loading and tissue engineering biomedical, and particularly relates to a porous Mxene membrane for drug loading and application thereof.
Background
The nanoparticle delivery system can enable the drug to be accumulated at a focus position through the high permeability and retention effect (EPR effect) of tumor cells, so that the nanoparticle delivery system is widely applied to the targeted delivery of chemotherapeutic drugs. The magnetic nanoparticles are considered to be ideal drug targeting delivery nanoparticles, and have the advantages of large specific surface area, stable chemical properties and high biocompatibility. Conventional Fe3O4The magnetic nano-particles belong to metal oxide base materials, and as a drug carrier, the surface of the nano-particles needs to be chemically modified, so that the surface activity of the nano-particles is favorably improved, the biocompatibility of the nano-particles is improved, and Fe3O4The nanoparticles are easily aggregated into clusters, which trigger a series of inflammatory reactions. As a drug carrier, the material is required to have high porosity, be mutually communicated, be biocompatible and degradable, and be discharged out of the body after the drug release is finished. The Mxene as a novel two-dimensional material has large interlayer distance and very large specific surface area, is an excellent carrier of a medicament, and can inhibit tumors and be biodegradable. The composite can better exert the potential and the drug release function of the material by combining the composite with drug-carrying components, and has great potential in the biomedical field of drug-carrying and tissue engineering.
Disclosure of Invention
In order to solve the above-mentioned deficiencies and drawbacks of the prior art, the present invention has as its primary object to provide a porous Mxene membrane for drug loading.
Another object of the present invention is to provide a drug-loaded porous Mxene membrane prepared as described above,
the invention further aims to provide application of the medicine-carrying porous Mxene membrane.
The purpose of the invention is realized by the following technical scheme:
a porous Mxene membrane for carrying drugs is prepared by blending and stirring Mxene dispersion liquid, a carbon-based material and polycaprolactone nanoparticles in an inert atmosphere, performing vacuum filtration to form a membrane, and annealing at 150-500 ℃; wherein, the Mxene is Mn+1XnTxN is 1 to 3, X is C or N, M is a transition metal element of Sc, Ti, Zr, Hf, V, Nb, Ta, Cr, Mo or Mn, TxRepresents a surface functional group, the surface functional group being-O, -OH or-F.
Preferably, the inert atmosphere is nitrogen, argon or helium.
Preferably, the carbon-based material is more than one of graphene, carbon nanotubes, carbon nanohorns or carbon quantum dots.
Preferably, the particle size of the polycaprolactone nanoparticles is 50-500 nm; the concentration of the Mxene dispersion liquid is 0.5-10 mg/mL.
Preferably, the mass ratio of the Mxene to the carbon-based material and the polycaprolactone in the Mxene dispersion liquid is 1: (0.1-10): (1-100).
Preferably, the annealing time is 1-10 h.
The drug-loaded porous Mxene membrane is prepared by adding the porous Mxene membrane into an organic solvent containing a loaded drug, grafting the loaded drug on the porous Mxene membrane, and drying the porous Mxene membrane at 30-80 ℃.
Preferably, the organic solvent is one or more of ethanol, diethyl ether, acetone, dichloromethane, chloroform, carbon disulfide, toluene, tetrahydrofuran, N-dimethylformamide, benzoic acid, or N-methylpyrrolidone.
Preferably, the drug-loaded drug is more than one of adriamycin, amphotericin, daunorubicin, gentamicin, amikacin, dexamethasone, prostaglandin E1 or flurbiprofen ethoxyethyl; the concentration of the drug-loaded substance in the organic solvent containing the drug-loaded substance is 0.01-50 wt%.
The medicine-carrying porous Mxene membrane is applied to the field of biological tissue engineering.
The adoption of the carbon-based material can further increase the Mxene interlayer spacing, so that the Mxene interlayer spacing can be better dispersed, and the polycaprolactone can be better wrapped by Mxene surface functional groups due to the existence of surface hydrophilic groups, so that spherical nanoparticles are obtained; and after annealing at high temperature, polycaprolactone in the film can be removed, and the porous few-layer Mxene film is obtained.
Compared with the prior art, the invention has the following beneficial effects:
1. the Mxene membrane for carrying the medicine has high porosity, can be efficiently combined with the carried medicine, has uniform particle size distribution, and can continuously and stably control the release of the medicine.
2. The Mxene membrane for carrying the medicine has high medicine carrying efficiency (more than 30 percent), because the Mxene interlamellar spacing is improved by doping the carbon-based material into the Mxene, spherical nano Mxene is obtained by combining the Mxene surface functional group and the polycaprolactone particle surface group, and then the porous Mxene membrane is obtained by annealing.
3. The method has the advantages of simple synthetic process, less by-products and high reaction efficiency.
Drawings
FIG. 1 shows Ti obtained in example 13C2SEM photograph of (a).
FIG. 2 shows porous Ti obtained in example 13C2Physical picture of the membrane.
Detailed Description
The invention is further described in the following description with reference to the figures and specific examples, which should not be construed as limiting the invention. Unless otherwise specified, the technical means used in the examples are conventional means well known to those skilled in the art. Reagents, methods and apparatus used in the present invention are conventional in the art unless otherwise indicated.
The Mxene in the embodiment of the invention is Mn+1XnTxN is 1 to 3, X is C or N, M is a transition metal element of Sc, Ti, Zr, Hf, V, Nb, Ta, Cr, Mo or Mn, TxRepresents a surface functional group, the surface functional group being-O, -OH or-F.
Example 1
1. Preparation: in N2Next, 100mL of a solution containing 0.8g of Ti was added3C2Mixing the solution, 0.2g of carbon nano tube and 1.6g of polycaprolactone nano particles (50nm), stirring for 4h, and performing vacuum filtration to form a film; annealing at 300 ℃ to remove polycaprolactone, and drying in a vacuum drying oven at 50 ℃ for 24h to obtain porous Ti3C2A film;
2. porous Ti3C2Soaking the membrane in DMF solution containing 1.5 wt% of adriamycin for 24h, and drying to obtain Ti loaded with adriamycin3C2And (3) a membrane.
And (3) performance testing: FIG. 1 shows Ti obtained in this example3C2SEM photograph of (a). As can be seen from FIG. 1, Ti3C2Has obvious laminated structure. Porous Ti obtained in example3C2Physical picture of the membrane. As can be seen from FIG. 2, the obtained porous Ti3C2The membrane is flexible and can be bent. The obtained adriamycin-loaded porous Ti3C2The membrane is used for culturing breast cancer cells (mcf-7), the encapsulation rate reaches 25.8 percent, the accumulative release efficiency of the adriamycin is stable and durable in drug release and can reach 80 percent, and the mass loss after 14 days of culture is 38.1 percent.
Example 2
1. Preparation: 150mL of V containing 1.0g4C3Mixing and stirring the solution, 0.5g of graphene and 10g of polycaprolactone (100nm), and performing vacuum filtration to form a film; annealing at 450 deg.C to remove polycaprolactone, and vacuum drying at 50 deg.C for 24 hr to obtain porous V4C3A film;
2. a plurality of holes V4C3Soaking the membrane in dichloromethane solution containing 3.5 wt% of gentamicin for 24h, and drying to obtain gentamicin-loaded V4C3And (3) a membrane.
And (3) performance testing: the obtained V carrying gentamicin4C3The membrane is used for culturing human osteosarcoma cells (HOS), the encapsulation rate reaches 28.7%, the accumulation and release rate of gentamicin is 78.8%, and the mass loss amount is 27.8% after 3 days of culture.
Example 3
1. Preparation: 100mL of a solution containing 1.0g of Ta4C3Mixing and stirring the solution, 10g of graphene and 10g of polycaprolactone particles (150nm), and performing vacuum filtration to form a film; annealing at 350 ℃ to remove polycaprolactone, drying in a vacuum drying oven at 50 ℃ for 24h to obtain porous Ta4C3A film;
2. porous Ta4C3Soaking the membrane in a mixed solution containing 2.5 wt% of adriamycin, dichloromethane and toluene for 24 hours, and drying to obtain the Ta carrying the drug4C3And (3) a membrane.
And (3) performance testing: the obtained Ta carrying the medicine4C3The membrane is used for culturing osteoblasts, the encapsulation rate reaches 34.2%, the cumulative release rate of the adriamycin medicine is 83.9%, the release is stable and lasting, and the loss of nanoparticles is 56.8% after 28 days of culture.
Example 4
1. Preparation: 120mL of a solution containing 0.2g of Nb4C3Mixing and stirring the solution, 2g of graphene and 5g of polycaprolactone particles (50nm), and carrying out vacuum filtration to form a film; annealing at 250 ℃ to remove polycaprolactone, and drying in a vacuum drying oven at 50 ℃ for 24h to obtain porous Nb4C3A film;
2. mixing porous Nb4C3Soaking the membrane in a mixed solution containing 3.5 wt% of daunorubicin and NMP for 24h, and drying to obtain drug-loaded Nb4C3And (3) a membrane.
And (3) performance testing: carrying the obtained drug Nb4C3The membrane is used for culturing human osteosarcoma cells, the encapsulation rate reaches 33.2%, the cumulative release rate of daunorubicin drugs reaches 78.5%, the stability is long, and the mass loss of nanoparticles is 33.8% after 7 days of culture.
The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other changes, modifications, substitutions, combinations and simplifications which do not depart from the spirit and principle of the present invention should be construed as equivalents thereof, and all such changes, modifications, substitutions, combinations and simplifications are intended to be included in the scope of the present invention.

Claims (10)

1. The porous Mxene membrane for drug loading is characterized in that under an inert atmosphere, Mxene dispersion liquid, a carbon-based material and polycaprolactone nanoparticles are blended and stirred, then vacuum filtration is carried out to form a membrane, and annealing is carried out at 150-500 ℃ to obtain the porous Mxene membrane; wherein, the Mxene is Mn+1XnTxN is 1 to 3, X is C or N, M is a transition metal element of Sc, Ti, Zr, Hf, V, Nb, Ta, Cr, Mo or Mn, TxRepresents a surface functional group, the surface functional group being-O, -OH or-F.
2. A porous Mxene membrane for drug loading according to claim 1, wherein the inert atmosphere is nitrogen, argon or helium.
3. The porous Mxene membrane for medicine loading of claim 1, wherein the carbon-based material is more than one of graphene, carbon nanotube, carbon nanohorn or carbon quantum dot.
4. The porous Mxene membrane for drug loading according to claim 1, wherein the particle size of the polycaprolactone nanoparticles is 50-500 nm; the concentration of the Mxene dispersion liquid is 0.5-10 mg/mL.
5. The porous Mxene membrane for drug loading according to claim 1, wherein the mass ratio of the Mxene to the carbon-based material and polycaprolactone in the Mxene dispersion liquid is 1: (0.1-10): (1-100).
6. The porous Mxene membrane for drug loading according to claim 1, wherein the annealing time is 1-10 h.
7. The drug-loaded porous Mxene membrane is characterized in that the drug-loaded porous Mxene membrane is prepared by adding the porous Mxene membrane of any one of claims 1 to 6 into an organic solvent containing a loaded drug to graft the loaded drug, and drying at 30-80 ℃.
8. The drug-loaded porous Mxene membrane of claim 7, wherein the organic solvent is one or more of ethanol, diethyl ether, acetone, dichloromethane, chloroform, carbon disulfide, toluene, tetrahydrofuran, N-dimethylformamide, benzoic acid, or N-methylpyrrolidone.
9. The drug-loaded porous Mxene membrane of claim 7, wherein the drug-loaded substance is one or more of doxorubicin, amphotericin, daunorubicin, gentamicin, amikacin, dexamethasone, prostaglandin E1, or flurbiprofen ethoxyethyl ester; the concentration of the drug-loaded substance in the organic solvent containing the drug-loaded substance is 0.01-50 wt%.
10. Use of a drug-loaded porous Mxene membrane according to any of claims 7 to 9 in the field of biological tissue engineering.
CN202010064927.7A 2020-01-20 2020-01-20 Porous Mxene membrane for drug loading and application thereof Active CN111110913B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010064927.7A CN111110913B (en) 2020-01-20 2020-01-20 Porous Mxene membrane for drug loading and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010064927.7A CN111110913B (en) 2020-01-20 2020-01-20 Porous Mxene membrane for drug loading and application thereof

Publications (2)

Publication Number Publication Date
CN111110913A true CN111110913A (en) 2020-05-08
CN111110913B CN111110913B (en) 2022-04-08

Family

ID=70491514

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010064927.7A Active CN111110913B (en) 2020-01-20 2020-01-20 Porous Mxene membrane for drug loading and application thereof

Country Status (1)

Country Link
CN (1) CN111110913B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109825734A (en) * 2019-04-01 2019-05-31 江西理工大学 Collaboration enhancing Cu-base composites and preparation method thereof
CN115177791A (en) * 2021-04-02 2022-10-14 苏州北科纳米科技有限公司 Preparation and application of MXenes biological coating with good biocompatibility

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104733712A (en) * 2015-03-20 2015-06-24 华东理工大学 Preparation method of transition metal oxide/carbon-based laminated composite material
CA2971589A1 (en) * 2014-12-18 2016-06-23 Edico Genome Corporation Chemically-sensitive field effect transistor
CN108245682A (en) * 2018-02-11 2018-07-06 中国人民解放军第二军医大学 The mesoporous MXene nanometer sheets pharmaceutical carrier of acidity, photothermal response type and preparation method
CN108273058A (en) * 2018-02-11 2018-07-13 中国人民解放军第二军医大学 A kind of neoplasm targeted therapy sustained release preparation and preparation method thereof
CN109671576A (en) * 2018-12-12 2019-04-23 福建翔丰华新能源材料有限公司 Carbon nano tube-MXene composite three-dimensional porous carbon material and preparation method thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2971589A1 (en) * 2014-12-18 2016-06-23 Edico Genome Corporation Chemically-sensitive field effect transistor
CN104733712A (en) * 2015-03-20 2015-06-24 华东理工大学 Preparation method of transition metal oxide/carbon-based laminated composite material
CN108245682A (en) * 2018-02-11 2018-07-06 中国人民解放军第二军医大学 The mesoporous MXene nanometer sheets pharmaceutical carrier of acidity, photothermal response type and preparation method
CN108273058A (en) * 2018-02-11 2018-07-13 中国人民解放军第二军医大学 A kind of neoplasm targeted therapy sustained release preparation and preparation method thereof
CN109671576A (en) * 2018-12-12 2019-04-23 福建翔丰华新能源材料有限公司 Carbon nano tube-MXene composite three-dimensional porous carbon material and preparation method thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZEHANG ZHOU ET AL.: "《Layer-by-layer assembly of MXene and carbon nanotubes on electrospun polymer films for flexible energy storage》", 《NANOSCALE》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109825734A (en) * 2019-04-01 2019-05-31 江西理工大学 Collaboration enhancing Cu-base composites and preparation method thereof
CN115177791A (en) * 2021-04-02 2022-10-14 苏州北科纳米科技有限公司 Preparation and application of MXenes biological coating with good biocompatibility

Also Published As

Publication number Publication date
CN111110913B (en) 2022-04-08

Similar Documents

Publication Publication Date Title
Onyancha et al. Facile synthesis and applications of carbon nanotubes in heavy-metal remediation and biomedical fields: a comprehensive review
Chaudhuri et al. Myoblast differentiation of human mesenchymal stem cells on graphene oxide and electrospun graphene oxide–polymer composite fibrous meshes: importance of graphene oxide conductivity and dielectric constant on their biocompatibility
CN111110913B (en) Porous Mxene membrane for drug loading and application thereof
Luo et al. Carbon nanotube nanoreservior for controlled release of anti-inflammatory dexamethasone
Jatoi et al. Cellulose acetate/multi-wall carbon nanotube/Ag nanofiber composite for antibacterial applications
Ha et al. Novel silicificated PVAc/POSS composite nanofibrous mat via facile electrospinning technique: potential scaffold for hard tissue engineering
CN111013579B (en) Limited-area carbon material loaded with palladium single atom or palladium nano-particles and preparation method thereof
CN109879278B (en) Preparation method of zero-dimensional-two-dimensional hybrid laminated superstructure nano material
Bosi et al. Carbon nanotubes in tissue engineering
Akia et al. Synthesis of multiwall α-Fe2O3 hollow fibers via a centrifugal spinning technique
KR20130082460A (en) Cnt and method for manufacturing thereof
CN111892095A (en) MoS2Preparation method of multi-element transition metal sulfide composite material
CN115888729A (en) Catalyst for mass production of multi-walled carbon nanotubes
CN112830464A (en) Strontium-doped hydroxyapatite nanotube and preparation method thereof
Ranjbar Bahadori et al. Synthesis of cobalt, palladium, and rhenium nanoparticles
Zheng et al. Microwave-assisted facile synthesis of mono-dispersed Ba/Ho co-doped nanohydroxyapatite for potential application as binary CT imaging contrast agent
Sharon et al. Carbon nanomaterials: Applications in physico-chemical systems and biosystems
Uddin et al. Recent Progress on Synthesis of 3D Graphene, Properties, and Emerging Applications
Tevlek et al. Synthesis of conductive carbon aerogels decorated with β-tricalcium phosphate nanocrystallites
McCafferty et al. Decoration of multiwalled carbon nanotubes with protected iron nanoparticles
Aram et al. Carbon-based nanostructured composites for tissue engineering and drug delivery
KR20180106013A (en) SHAPE-CONTROLLED Pt NANOCUBES AND METHOD OF MANUFACTURE THEREOF
Soltani et al. Recent trends in the design and engineering of incorporated carbon nanofiber nanocomposites and their advanced applications–a review
Gao et al. Bio-inspired growth of silver nanoparticles on 2D material’s scaffolds as heterostructures with their enhanced antibacterial property
KR20130009478A (en) Nanocomposites comprising with calcium phosphate adsorbed modified carbon nanotubes and degradable polymer and method of preparing thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant